Nisa Investment Advisors
SPRY icon

Nisa Investment Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Nisa Investment Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.3K Sell
5,647
-14,973
-73% -$143K ﹤0.01% 1705
2025
Q4 		$240K Buy
20,620
+14,367
+230% +$140K ﹤0.01% 1187
2025
Q3 		$62.8K Sell
6,253
-28
-0.4% -$402 ﹤0.01% 1567
2025
Q2 		$110K Buy
6,281
+590
+10% +$8.51K ﹤0.01% 1365
2025
Q1 		$71.6K Sell
5,691
-84
-1% -$1.01K ﹤0.01% 1485
2024
Q4 		$60.9K Buy
5,775
+84
+1% +$1.18K ﹤0.01% 1627
2024
Q3 		$82.5K Hold
5,691
– – ﹤0.01% 1502
2024
Q2 		$48.4K Buy
5,691
+91
+2% +$808 ﹤0.01% 1680
2024
Q1 		$57.2K Hold
5,600
– – ﹤0.01% 1620
2023
Q4 		$30.7K Buy
5,600
+5,575
+22,300% +$24.4K ﹤0.01% 1750
2023
Q3 		$95 Buy
+25
New +$164 ﹤0.01% 2736
2022
Q2 		– Sell
-4,100
Closed -$14K – 2500
2022
Q1 		$14K Buy
+4,100
New +$17.8K ﹤0.01% 2141

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Nisa Investment Advisors's SPRY Position: Q1 2026 in Review

Nisa Investment Advisors reduced its ARS Pharmaceuticals (SPRY) stake by 73% in Q1 2026, selling an estimated $143K and leaving 5,647 shares worth $45.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1705.

Nisa Investment Advisors first reported a position in SPRY in Q1 2022 and has held it in 12 quarters since. The position peaked at $240K in Q4 2025. 203 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Nisa Investment Advisors held 5,647 shares of ARS Pharmaceuticals worth $45.3K as of Q1 2026.
  • Nisa Investment Advisors sold 14,973 ARS Pharmaceuticals shares in Q1 2026, an estimated $143K.
  • ARS Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #1705 holding.
  • Nisa Investment Advisors first reported a position in ARS Pharmaceuticals in Q1 2022 and has held it in 12 quarters since.
  • Nisa Investment Advisors's ARS Pharmaceuticals position peaked at $240K in Q4 2025.
  • 203 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.